Loading...
Diffuse large B-cell lymphoma (DLBCL) arising in patients with preexisting chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), designated as Richter transformation, is associated with poor response and short survival following immunochemotherapy. Investigators now report a prospective, multicenter, phase 2 trial of the programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab (A), the BCL2 inhibitor venetoclax (V), and the anti-CD20 antibody obinutuzumab (O) in patients with documented CLL/SLL, biopsy-proven DLBCL, no prior treatment with study agents, and no prior DLBCL-directed therapy. Patients received AVO in cycles 1 to 8, AV in cycles 9 to 18, and single-agent V in cycles 19 to 35.
Among the key findings:
Of the 28 pa…